Ciltacabtagene autoleucel (Carvykti®) for the treatment of relapsed and refractory multiple myeloma (MM). Update June 2022

Rothschedl, E. and Wolf, S. (2022): Ciltacabtagene autoleucel (Carvykti®) for the treatment of relapsed and refractory multiple myeloma (MM). Update June 2022. Oncology Fact Sheet Nr. 86.

[thumbnail of Oncology Fact Sheet Nr.86_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
111kB

Item Type:	Oncology Fact Sheet
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WH Hemic and lymphatic systems
Language:	English
Series Name:	Oncology Fact Sheet Nr. 86
Deposited on:	25 Apr 2022 14:21
Last Modified:	11 Jul 2022 13:37

Repository Staff Only: item control page